Volume | 151,674 |
|
|||||
News | (1) | ||||||
Day High | 4.25 | Low High |
|||||
Day Low | 3.86 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Tenax Therapeutics Inc | TENX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.94 | 3.86 | 4.25 | 3.87 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
782 | 151,674 | $ 4.07 | $ 616,730 | - | 3.48 - 61.152 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:53:33 | 15 | $ 4.25 | USD |
Tenax Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.2M | 298.28k | - | 0 | -11.05M | -37.04 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Tenax Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TENX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.96 | 4.25 | 3.48 | 3.80 | 45,529 | 0.25 | 6.31% |
1 Month | 4.21 | 5.1695 | 3.48 | 4.48 | 153,575 | 0.00 | 0.00% |
3 Months | 15.72 | 21.4599 | 3.48 | 8.90 | 368,862 | -11.51 | -73.22% |
6 Months | 23.888 | 61.152 | 3.48 | 43.41 | 3,812,906 | -19.68 | -82.38% |
1 Year | 40.704 | 61.152 | 3.48 | 40.96 | 2,270,434 | -36.49 | -89.66% |
3 Years | 3,264.00 | 3,952.00 | 3.48 | 338.29 | 1,673,068 | -3,259.79 | -99.87% |
5 Years | 3,504.00 | 5,888.00 | 3.48 | 1,085.49 | 1,379,471 | -3,499.79 | -99.88% |
Tenax Therapeutics Description
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com. |